Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) Given Consensus Rating of “Buy” by Brokerages

Shares of Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) have received a consensus rating of “Buy” from the five ratings firms that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $15.3333.

RADX has been the subject of a number of research reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Radiopharm Theranostics in a research note on Thursday, January 22nd. B. Riley Financial reiterated a “buy” rating and issued a $16.00 price target (up previously from $13.00) on shares of Radiopharm Theranostics in a report on Tuesday, December 16th. Finally, Wall Street Zen lowered shares of Radiopharm Theranostics to a “strong sell” rating in a report on Friday, January 23rd.

Radiopharm Theranostics Stock Performance

Shares of Radiopharm Theranostics stock opened at $4.79 on Wednesday. The business has a 50-day moving average of $5.17 and a two-hundred day moving average of $5.39. Radiopharm Theranostics has a 1 year low of $3.50 and a 1 year high of $16.25.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of RADX. PNC Financial Services Group Inc. acquired a new stake in Radiopharm Theranostics in the 2nd quarter valued at approximately $37,000. Marex Group plc bought a new position in shares of Radiopharm Theranostics during the 4th quarter worth approximately $54,000. Finally, Jane Street Group LLC acquired a new stake in shares of Radiopharm Theranostics in the fourth quarter valued at approximately $76,000.

Radiopharm Theranostics Company Profile

Radiopharm Theranostics, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of radiopharmaceutical products for both diagnostic imaging and targeted radiotherapeutic applications. By harnessing the unique properties of radioisotopes, the company aims to improve the precision of disease detection and deliver therapeutic payloads directly to diseased tissues, particularly in oncology.

The company’s research and development efforts are concentrated on a pipeline of radioligand therapies and companion diagnostic agents designed to address a variety of tumor types.